The availability of structural information on glycosyltransferases is beginning to make structure-based reengineering of these enzymes possible. Mutant glycosyltransferases have been generated that can transfer a sugar residue with a chemically reactive unique functional group to a sugar moiety of glycoproteins, glycolipids, and proteoglycans (glycoconjugates). The presence of modifi ed sugar moiety on a glycoprotein makes it possible to link bioactive molecules via modifi ed glycan chains, thereby assisting in the assembly of bionanoparticles that are useful for developing the targeted drug delivery system and contrast agents for magnetic resonance imaging. The reengineered recombinant glycosyltransferases also make it possible to (1) remodel the oligosaccharide chains of glycoprotein drugs, and (2) synthesize oligosaccharides for vaccine development.
INTRODUCTION
Because of the many physiological barriers that must be overcome, targeting drugs to the proposed site of action is a challenging task. The passage of a drug across the endothelium is dependent upon several factors, including its molecular weight and size. Small molecules are taken up by a cell: a process that generally involves a specifi c transport mechanism or a passive diffusion process. In contrast, uptake of macromolecules by a cell involves receptormediated endocytosis or pinocytososis. [1] [2] [3] These processes involve the interactions between the ligand and the receptors. 4 , 5 Since oligosaccharides are attached at unique sites in proteins and glycolipids, they bring about specifi c geometries of interactions between the 2 glycoconjugates, resulting in the correct and effi cient molecular interplay between various molecular structures. Owing to their conformational fl exibility, the torsional angles of a disaccharide unit, particularly around the 1-6-linkage, adjust in a way that causes the side groups of the oligosaccharides to orient themselves in a manner that produces specifi c protein-carbohydrate or proteinprotein interactions. 6 Branched oligosaccharides cross-link proteins and generate homo-and heterodimerization of glycoproteins and infi nite networks of protein-carbohydrate complexes, [7] [8] [9] resulting in the modulation of various cellular responses.
Oligosaccharides participate in a large number of biological events, such as cell-cell recognition and adhesion, [10] [11] [12] [13] hostpathogen interactions, [14] [15] [16] innate and acquired immunity, 17 , 18 and the recruitment of neutrophils to sites of tissue damage. 19 Together with chaperones, they play an important role in the in vivo folding and transport of glycoproteins across cellular compartments. [20] [21] [22] They are also the recognition molecules for lectins, the multivalent carbohydrate binding proteins widely found in nature. 23 In animals, a family of ␤ -galactoside binding proteins known as galectins perform several intracellular activities, namely, cell cycle control, anti-apoptosis, and RNA processing. 24 , 25 Also, glycosaminoglycans, the carbohydrate moieties of proteoglycans, take part in a wide range of biological functions. 26 For example, glycosaminoglycans are involved in the formation of an extracellular matrix to which growth factors bind with a high degree of specifi city and, thereby, regulate growth factor activity. [27] [28] [29] [30] Because oligosaccharide moieties of glycoconjugates are involved in many biological processes, they have been used as a tool for the delivery of ligands to specifi c sites and tissues. The discovery of the hepatic receptor, the asialoglycoprotein receptor (ASGPR), which binds to and internalizes the circulating glycoproteins or glycopeptides that have galactose or N -acetylgalactosamine residue at the nonreducing terminus of the oligosaccharide chain, 31 facilitated " glycotargeting," the use of carbohydrate ligands to target protein receptors at the site of location. [32] [33] [34] [35] Here we describe
OLIGOSACCHARIDE BIOSYNTHESIS AND GLYCOSYLTRANSFERASES
The biosynthesis of oligosaccharide chains of glycoconjugates involves intricate machinery in a cell, where, from a small number of saccharide units, diverse oligosaccharide structures are generated through isomeric linkages between sugars, each linkage catalyzed by a different enzyme. 36 This large family of enzymes, called glycosyltransferases, is involved in the assembly of oligosaccharide chains, each enzyme transferring a monosaccharide moiety of an activated sugar donor to an oligosaccharide acceptor molecule. These enzymes often require a metal ion cofactor. They are grouped into families based on the type of sugar they transfer (eg, galactosyltransferase, [37] [38] [39] fucosyl transferase, 40 sialyltransferase, 41 polypeptide-N-acetylgalactosaminyltransferase, 42 O-xylosyltransferase, 43 blood group A and B transferases 44 ), and within the family there are subfamilies and members. Each transferase generates a specifi c linkage with a specifi c acceptor. These enzymes reside in the secretory pathway, although some have also been shown to be present at the cell surface interacting with the cell matrix. 45 , 46 They have been implicated as signaling molecules for pattern formation during development. [47] [48] [49] Chemical structures of many carbohydrate moieties change during cellular development, differentiation, and tumorigenesis. [50] [51] [52] The synthesis of these carbohydrate moieties depends on the expression of corresponding glycosyltransferases in the cell. Alterations in glycosyltransferase activities that result in the defective glycan synthesis have been shown to have serious pathological consequences leading to several human diseases. 53 
GENERAL STRUCTURAL FEATURES OF GLYCOSYLTRANSFERASES
Recent structural analysis of the catalytic domain of several glycosyltransferases have revealed that these enzymes are globular proteins that have 2 types of fold, termed GT-A and GT-B, each having an N-terminal and a C-terminal domain. 54 , 55 The enzymes of the GT-A fold have 2 dissimilar domains. Mammalian galactosyltransferases (Gal-T), N -acetylglucosaminyltransferases (Gln-T), glucuronyltransferases (GlcA-T), and blood groups A and B transferases have GT-A fold. The N-terminal domain, which recognizes the sugar-nucleotide donor, comprises several ␤ -strands that are each fl anked by ␣ -helices, as in a Rossmann-like fold, whereas the C-terminal domain, which contains the acceptor binding site, consists largely of mixed ␤ -sheets. By contrast, enzymes with the GT-B fold contain 2 similar Rossmann-like folds, with the N-terminal domain providing the acceptor binding site and the C-terminal domain providing the donor binding site. Fungal and phage glucosyltransferases belong to this fold. In both types of enzyme, the 2 domains are connected by a linker region, and the active site is located between the 2 domains. A metal binding site is also located in the cleft in enzymes of both the GT-B and GT-A fold.
The structural work performed on the ␤ -1,4-galactosyltransferase-1 ( ␤ 4Gal-T1) in our laboratory, 56 and on other glycosyltransferases by various other laboratories, 55 has shown that, upon binding the sugar-nucleotide donor substrate, fl exible loops at the substrate binding site of these enzymes undergo a marked conformational change, from an open to a closed conformation 55 ( Figure 1 ). This change creates an oligosaccharide acceptor binding site in the enzyme that did not exist before. The loop then acts as a lid covering the bound donor substrate. After the transfer of the glycosyl unit to the acceptor, the saccharide product is ejected, and the loop reverts to its native conformation to Figure 1 . Molecular structure of ␤ 4Gal-T1 in closed conformation, in complex with UDP-Gal and Mn 2+ . The long fl exible loop (orange loop, residues Ile345-His365) and the small fl exible loop (yellow, residues Gly313-Gly316) are in closed conformation. The Trp314 (W314) side chain is facing toward the binding pocket that is interacting with UDP-Gal. The 3 protein ligands, Asp (D254), Met (M344), and His (H347), the 2 phosphate oxygens (red balls), and 1 molecule of water (yellow ball) participate in the coordination of Mn 2+ . 56 The acceptor binding site (shown with arrow) involves 2 Tyr residues, Y289 and Y286, and Phe (F360). The enzyme can be considered as a 2-domain protein, one ␣ -helix rich and the other ␤ -sheet rich, with substrates binding between the domains.
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release the remaining nucleotide moiety. This conformational change in ␤ 4Gal-T1 also creates the binding site for ␣ -lactalbumin, a protein produced in the mammary glands during lactation. The interaction of ␣ -lactalbumin with ␤ 4Gal-T1 changes the acceptor specifi city of the enzyme from N -acetylglucosamine (GlcNAc) to glucose (Glc), which produces lactose that is secreted in milk.
A FEW PROTEIN RESIDUES IN ACTIVE SITE DETERMINE DONOR SPECIFICITY OF GLYCOSYLTRANSFERASES
The specifi city of the sugar donor is determined by a few residues in the sugar-nucleotide binding pocket of the enzyme, which are conserved among the family members from different species 55 ( Figure 1 ). For example, a highly conserved tyrosine residue in ␤ 4Gal-T subfamily members (Tyr289 in bovine ␤ 4Gal-T) determines enzyme specifi city toward the galactose moiety of the sugar donor ( Figure 2 ) . 57 By forming a hydrogen bond with its N-acetyl group, it restricts the transfer of GalNAc moiety from uridine 5′-diphosphate (UDP)-GalNAc to GlcNAc ( Figure 2A ). Mutation of Tyr289 to leucine, isoleucine, or asparagine, however, makes the enzyme as effi cient as a galactose-or GalNActransferase ( Figure 2B ). 57 In GlcA-TI, the N ⑀ 2 nitrogen of His308 (His311 in GlcAT-P) forms a hydrogen bond with the 2-hydroxyl of GlcUA, 58 , 59 which determines enzyme specifi city toward UDP-GlcUA as the sugar donor. Substitution of His308 with arginine in GlcAT-I enables the enzyme to effi ciently use UDP-Glc, UDP-Man, or UDPGlcNAc as the donor substrates. 60 Met266 and Ala268 in the blood group B Gal-T, and Leu266 and Gly268 in the blood group A GalNAc transferase, determine specifi city toward their respective sugar donors, UDP-Gal and UDPGalNAc. 61 Spontaneous mutation of a residue that confers donor specifi city to a residue that broadens it, such as the mutation of tyrosine to isoleucine in ␤ 4Gal-T1 or histidine to arginine in GlcAT-I, will result in cellular glycans with altered sugar residues and could have signifi cant effects on normal cellular processes.
MUTATIONS OF DONOR BINDING RESIDUES BROADEN DONOR SPECIFICITY OF THE ENZYME: MUTANT ENZYME Y289L-GAL-T1 TRANSFERS 2-KETO-GALACTOSE TO GLCNAC RESIDUE
Based on the structural information, mutant enzymes have been generated that have broader donor-sugar specifi city. 57 , 62 Tyr289 residue in bovine ␤ 4Gal-T 1, and Tyr or Phe residue at the corresponding positions in other ␤ 4Gal-T family members of various species determine the specifi city toward the donor sugar nucleotide UDP-Gal. Mutation of Tyr289 to Leu or Ile both abrogates the hydrogen-bonding capacity as well as enlarges the binding pocket such that the mutant enzymeY289L-Gal-T transfers GalNAc from the donor substrate UDP-GalNAc with as good effi ciency as Gal from UDP-Gal ( Figure 2B ) . The mutant enzyme Y289L-Gal-T can also transfer from the UDP derivative the galactose moiety that has substitutions other than the 2-N -acetyl group (eg, -CH 2 -CO-CH 3 , located at the C-2 position 63 ) ( Figure 3A ) . The ketone moiety of the substituting group is a versatile chemical handle. Under mild conditions (pH 6.7 buffer, 25°C), it can be coupled to an aminooxy biotin derivative, N -(aminooxyacetyl)-N' -(D-biotinoyl) hydrazine ( Figure 3B ). The biotinylated product can then be detected with streptavidin-horse radish peroxidase (HRP). 63 
COUPLING OF GLYCOPROTEINS VIA OLIGOSACCHARIDE CHAINS AND THE GENERAL UTILITY OF THE TECHNIQUE
The availability of mutant glycosyltransferases makes it possible to transfer sugar moieties with a variety of functional groups from their respective donor nucleotides 63 , 64 to a specifi c residue of an oligosaccharide chain of a glycoprotein. The 2 glycoproteins, each carrying the sugar moiety with reactive functional groups, can then be coupled by heterobifunctional linkers ( Figure 4 ), thus enabling 2 glycoproteins to be coupled at a specifi c site. One glycoprotein can be a monoclonal antibody, which carries a single N -linked oligosaccharide chain on the immunoglobulin G (IgG) heavy chain, while another can be a toxin. This coupling allows a controlled and specifi c linking of monoclonal antibodies to toxins. Furthermore, the monoclonal antibodies whose N -linked glycan moiety has been modifi ed to have 2-keto-galactose can be linked to aminooxy linkers carrying chelating agents specifi c for gadolinium or other contrast agents for imaging.
In the currently prevailing methods, generally 2 proteins are cross-linked, using a bifunctional cross-linker, at random sites to a protein residue (eg, lysine), which is distributed at several places on the protein surface. This method of crosslinking often blocks the functional sites on the protein and thus reduces the bioeffi cacy of the protein. In contrast, the advantage of the method described here, in which 2 glycoproteins or glycoconjugates are linked via glycan chains, is that the linkage between the 2 partners is at a defi ned site, where glycan moiety is attached to the glycoconjugates. For example, a cargo can be attached to a monoclonal antibody at the aspargine-linked glycan chain, which resides in the Fc-fragment, away from the antigen binding site, and delivered to the site of action without altering the bioeffi cacy of the monoclonal antibody.
CONCLUSIONS
The structural information of glycosyltransferases has made it possible to design novel glycosyltransferases with broader and requisite donor specifi cities. The specifi city of the donor sugar of these enzymes is determined by a few residues in their sugar-nucleotide binding pocket, which are conserved among the family members from different species. Based on the structural information and conformational analysis of oligosaccharide chains, we have been able to design novel glycosyltransferases with broader donor and acceptor specifi cities. Several mutant glycosyltransferases have been generated that can transfer a sugar residue with a chemically reactive functional group to N-acetylglucosamine residue of a glycoconjugate. The modifi ed oligosaccharide moieties of glycoconjugates can then be used for linking bioactive molecules via glycan chains, thereby assisting in the assembly of bionanoparticles that are useful for developing the targeted drug delivery system and contrast agents for MRI.
